<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086865</url>
  </required_header>
  <id_info>
    <org_study_id>E02-CIF-APE-02-08</org_study_id>
    <nct_id>NCT01086865</nct_id>
  </id_info>
  <brief_title>Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.</brief_title>
  <acronym>Apetiviton BC</acronym>
  <official_title>Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cifarma Cientifica Farmaceutica Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cifarma Cientifica Farmaceutica Ltda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study phase III, randomized, double-blind, prospective, comparative non-inferiority&#xD;
      to evaluate the efficacy and tolerability of using APETIVITON BC compared to Petivit BC in&#xD;
      appetite stimulate in children, adults and elderly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial phase III, randomized, double-blind, prospective, comparative non-inferiority&#xD;
      to evaluate the efficacy and tolerability of using APETIVITON BC compared to Petivit BC&#xD;
      stimulation of appetite in children, adults and elderly. A total of 150 patients, distributed&#xD;
      as follows:&#xD;
&#xD;
      25 patients treated children Apetiviton BC,25 patients treated children Petivit BC, (2-6&#xD;
      years).&#xD;
&#xD;
      25 adult patients treated with Apetiviton BC,25 adult patients treated with Petivit BC,&#xD;
      (18-50 years.&#xD;
&#xD;
      25 elderly patients treated with Apetiviton BC,25 elderly patients treated with Petivit BC.&#xD;
      (60-80 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effectiveness of apetiviton BC compared to Petivit BC in appetite stimulation in children, adults and seniors.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the tolerability of apetiviton BC compared to Petivit BC the stimulation of appetite in children, adults and seniors</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Inappetence</condition>
  <arm_group>
    <arm_group_label>Petivit BC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Apetiviton BC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apetiviton BC</intervention_name>
    <description>Administer the recommended dosage preferably one hour before the main meal:&#xD;
Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily.</description>
    <arm_group_label>Apetiviton BC</arm_group_label>
    <arm_group_label>Petivit BC</arm_group_label>
    <other_name>Petivit Bc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          -  Patients who have inappetence;&#xD;
&#xD;
          -  Patients able to understand and maintain adherence to protocol;&#xD;
&#xD;
          -  Wash-out 20 days after ingestion of prior similar drug;&#xD;
&#xD;
          -  Patients able to understand the correct use of medication;&#xD;
&#xD;
          -  Patients who consent to participate in the study by signing the inform consent;&#xD;
&#xD;
        Children:&#xD;
&#xD;
          -  Patients of any ethnic group male and female, aged between 2 and 6 years;&#xD;
&#xD;
        Adults:&#xD;
&#xD;
          -  Patients of any ethnic group male and female, aged between 18 and 50 years;&#xD;
&#xD;
          -  Female patients in childbearing age, sexually active, make pregnancy test result&#xD;
             should be negative and, furthermore, should be using contraceptive methods such as&#xD;
             contraception, condom, IUD and diaphragm.&#xD;
&#xD;
        Elderly:&#xD;
&#xD;
          -  Patients of any ethnic group male and female, aged between 60 and 80 years.&#xD;
&#xD;
          -  Female patients in childbearing age, sexually active, make pregnancy test result&#xD;
             should be negative and, furthermore, should be using contraceptive methods such as&#xD;
             contraception, condom, IUD and diaphragm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          -  Patients with glaucoma open or closure angle;&#xD;
&#xD;
          -  Patients with predisposition to urinary retention;&#xD;
&#xD;
          -  Patients with stenous peptic ulcer or pylorus-duodenal obstruction;&#xD;
&#xD;
          -  Debilitated patients or in acute attack of asthma;&#xD;
&#xD;
          -  Alcoholic;&#xD;
&#xD;
          -  Patients who have loss of appetite caused by any serious disease;&#xD;
&#xD;
          -  Patients who make use of any drugs central nervous system depressants;&#xD;
&#xD;
          -  Patients who make use of medicines monoaminooxidase inhibitors, tricyclic&#xD;
             antidepressants, phenothiazines, probenecid, levodopa, phenytoin, phenobarbital,&#xD;
             chloramphenicol, cyclophosphamide, cyclosporine, chlorambucil, corticotropin,&#xD;
             mercaptopurine, isoniazid, penicillin, estrogens, contraceptives, haloperidol,&#xD;
             ipatrópico, barbiturates, primidone, salicylates;&#xD;
&#xD;
          -  Patients with known hypersensitivity to any components of the formula;&#xD;
&#xD;
          -  Patient who is participating in another clinical study;&#xD;
&#xD;
          -  No able to adhere to protocol;&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding;&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator can impossible to include the&#xD;
             patient's adherence to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>May 18, 2010</last_update_submitted>
  <last_update_submitted_qc>May 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sônia Silveira Braga</name_title>
    <organization>Cifarma Cientifica Farmaceutica Ltda</organization>
  </responsible_party>
  <keyword>inappetence</keyword>
  <keyword>apetiviton BC</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

